Sarepta Therapeutics announced refinancing transactions that delay approximately $700 million of convertible senior notes due in 2027, extending maturities to 2030 and beyond. This move strengthens Sarepta's capital structure amid recent challenges linked to its Duchenne muscular dystrophy gene therapy development. The refinancing provides the company enhanced liquidity to fully fund its pipeline and meet near-term obligations as it navigates regulatory hurdles and strategic restructuring efforts.